Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Chin. Displaying page 1 of 1.
    EudraCT Number: 2006-002833-19 Sponsor Protocol Number: SPD488-402 Start Date*: 2006-10-12
    Sponsor Name:Shire Pharmaceutical Development
    Full Title: A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism)
    Medical condition: Excessive facial hair in females (Facial hirsutism)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020112 Hirsutism LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005330-12 Sponsor Protocol Number: RAA06-003 Start Date*: 2006-05-11
    Sponsor Name:King's College London (IOP)
    Full Title: Omega-3 Fatty Acids Supplementation for Adolescent Boys with Attention Deficit Hyperactivity Disorder : a double-blind, randomized controlled trial
    Medical condition: Attention deficit / hyperactivity disorder (ADHD) is defined by DSM-IV criteria, which shows inattention, hyperactivity and impulsivity. ADHD is one of the most common child psychiatric disorders,...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000726-78 Sponsor Protocol Number: SPD488-401 Start Date*: 2004-12-02
    Sponsor Name:Shire Pharmaceuticals Group plc
    Full Title: A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women with Excessive Facial Hair
    Medical condition: Facial Hirsutism in Women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002058-30 Sponsor Protocol Number: RD.03.SPR.40162E Start Date*: 2011-11-24
    Sponsor Name:Galderma R&D SNC
    Full Title: Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period.
    Medical condition: Papulopustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004019-19 Sponsor Protocol Number: MDCO-ABP-15-01 Start Date*: 2016-04-14
    Sponsor Name:The Medicines Company
    Full Title: A phase II, two-part, multiple-dose, dose-finding, single-blind study to investigate the safety and efficacy of ABP-700 for procedural sedation in adult patients undergoing colonoscopy
    Medical condition: Sedation during elective colonoscopy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005501-22 Sponsor Protocol Number: LEO 80190-O23 Start Date*: 2008-04-22
    Sponsor Name:LEO Pharma A/S
    Full Title: Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas. The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldnes...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003365-41 Sponsor Protocol Number: LEO 80190-O22 Start Date*: 2008-01-10
    Sponsor Name:LEO Pharma A/S
    Full Title: Calcipotriol Plus Hydrocortisone Ointment Compared with Tacalcitol Ointment in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment co...
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas. The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldnes...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020690-17 Sponsor Protocol Number: ATX-101-10-16 Start Date*: 2010-10-12
    Sponsor Name:Kythera Biopharmaceuticals, Inc.
    Full Title: Phase 3, multicenter, randomized, double-blind, placebo-controlled study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area
    Medical condition: Subcutaneous fat in the submental area
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016251 Fat tissue increased PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004782-18 Sponsor Protocol Number: LEO 80190-O21 Start Date*: 2008-06-03
    Sponsor Name:LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)
    Full Title: Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/...
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) LV (Completed) CZ (Completed) SI (Completed) NL (Completed) BE (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004592-36 Sponsor Protocol Number: RD.03.SPR.29097 Start Date*: 2012-04-12
    Sponsor Name:Galderma R&D
    Full Title: Subjects’ satisfaction on pan facial aesthetic enhancement after treatment with Azzalure® and the Restylane® range
    Medical condition: Facial volume loss and dynamic wrinkles of the upper third of the face
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10040954 Skin wrinkling PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002179-91 Sponsor Protocol Number: MLE4901-101 Start Date*: 2017-01-17
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)
    Medical condition: Polycystic Ovary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002996-32 Sponsor Protocol Number: 12UK/DCsc04 Start Date*: 2012-11-12
    Sponsor Name:IBSA Institut Biochimique S.A.
    Full Title: Preliminary evaluation of the efficacy and local tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, administered locally prior to surgery for the prevention of post-operative pain a...
    Medical condition: post-surgical pain after lower third molar removal.
    Disease: Version SOC Term Classification Code Term Level
    15.0 100000004863 10036286 Post-operative pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2017-000066-29 Sponsor Protocol Number: RD.03.SPR.114384 Start Date*: 2017-05-15
    Sponsor Name:Galderma R&D
    Full Title: Subject reported outcomes on satisfaction, efficacy and safety with Luxerm® in the field-directed treatment of thin or non-hyperkeratotic and non-pigmented Actinic Keratosis of the face or the scalp
    Medical condition: Thin or non-hyperkeratotic and non-pigmented Actinic Keratosis on the face and scalp
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10020648 Hyperkeratoses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020691-28 Sponsor Protocol Number: ATX-101-10-17 Start Date*: 2010-12-09
    Sponsor Name:Kythera Biopharmaceuticals, Inc.
    Full Title: Phase 3, multicenter, randomized, double-blind, placebo-controlled study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area
    Medical condition: Subcutaneous fat in the submental area
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016251 Fat tissue increased PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000973-54 Sponsor Protocol Number: RD.03.SPR.29112 Start Date*: 2013-06-04
    Sponsor Name:Galderma R&D SNC
    Full Title: Multi-centre, randomized, investigator-blind, intra-individual active and vehicle-controlled study, comparing Metvix® Natural Daylight Photodynamic Therapy versus Metvix® conventional Photodynamic ...
    Medical condition: Mild and/or moderate Actinic Keratoses
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10020648 Hyperkeratoses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004338-13 Sponsor Protocol Number: 2013_36 Start Date*: 2014-12-08
    Sponsor Name:CHRU De Lille
    Full Title: Phase II study evaluating the interest of Vismodegib as neo-adjuvant treatment of basal cell carcinoma
    Medical condition: Male and female patients at least 18 years of age with histologically confirmed diagnoses of locally advanced BCC
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005555-80 Sponsor Protocol Number: V00400SB302 Start Date*: 2015-05-21
    Sponsor Name:Pierre Fabre Dermatologie represented by IRPF
    Full Title: Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study
    Medical condition: High risk infantile haemangioma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018814 Haemangioma PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005686-12 Sponsor Protocol Number: RD.03.SPR.29107 Start Date*: 2013-05-23
    Sponsor Name:Galderma R&D
    Full Title: Patient-reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea
    Medical condition: Erythema of rosacea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 18:32:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA